Prior authorization is a clinical review filed by the prescribing office before a pharmacy may bill the plan. The office submits records measured against published criteria, a reviewer at the pharmacy benefit manager applies them, and any approval carries an expiry date. Members cannot file it themselves, but they can obtain the criteria and make sure the submission answers them.
Obtain the criteria document before anything is submitted
Most stalled requests fail on evidence the reviewer expected and did not receive. The criteria are written down, usually in a policy document that names the drug and lists the elements required. Getting hold of that document first converts an opaque process into a checklist, and it is the single highest-value thing a member can do without clinical training.
The document is requested from the entity that administers the pharmacy benefit rather than from the pharmacy. On many plans that is a pharmacy benefit manager operating under a different name than the insurance card suggests, which is why calls placed to the medical side get routed in circles. Asking specifically for the coverage policy applied to this drug under this plan usually produces it.
Which of the two indications is being reviewed
This drug is approved both for weight reduction with long-term maintenance and for moderate to severe obstructive sleep apnea in adults with obesity. Plans commonly maintain separate criteria for each, because benefit exclusions are drafted around the condition treated rather than the molecule dispensed. A request filed against the wrong indication can be refused on a rule that does not apply to the patient’s actual situation.
Where sleep apnea is present, the review turns on different evidence: a diagnostic sleep study, a severity measure, and documentation of what has been tried. The trial supporting that indication studied tirzepatide in adults with obesity and obstructive sleep apnea and reported reductions in apnea-hypopnea index compared with placebo. Establishing which indication the office intends to submit under, before it is submitted, avoids a wasted cycle.
What reviewers look for and the form it must take
| Element | Accepted form | Frequent gap |
|---|---|---|
| Body mass index | Measured value with the date recorded | Self-reported or undated figure |
| Weight-related condition | Coded diagnosis in the chart | Mentioned in narrative only |
| Previous attempts | Drugs or programs tried, dates, outcome | Stated generally with no dates |
| Lifestyle component | Documented diet and activity plan | Assumed rather than recorded |
| Sleep apnea severity | Sleep study report with index value | Diagnosis without the study attached |
| Requested regimen | Strength, frequency, duration | Left to the pharmacy to infer |
Who actually decides, and who can overrule them
The reviewer applying the criteria works for the benefit administrator. The criteria themselves were adopted by the plan sponsor, which for a self-funded employer is the employer. That distinction matters when a request is refused on a rule rather than on clinical grounds, because the administrator has no authority to change a design the employer chose. Human resources or the benefits office is occasionally the faster route in those cases.
A peer-to-peer conversation, where the prescriber speaks directly with a clinician reviewer, is available on most plans and is underused. It suits cases where the chart supports the request but does not fit the checklist cleanly, which is common now that clinical obesity is increasingly defined by organ dysfunction and functional limitation rather than a weight ratio alone.
Timelines are outer limits, not service targets
Group health plans work to federal deadlines for pre-service decisions, with a shorter clock where a delay would jeopardize health. Medicare drug plans run their own schedule for coverage determinations, faster still when a prescriber supports an expedited request. Complete electronic submissions frequently return in a day or two, while incomplete ones can sit indefinitely, since asking for missing information generally suspends the clock rather than running it down.
The practical member task is confirming transmission. A meaningful share of requests that appear to be pending were never sent, or went to a fax line belonging to a different benefit. A reference number from the office settles it in one call.
Running a price check in parallel is sensible while a decision is pending, so a delay does not force an unplanned gap. Manufacturer self-pay is the anchor figure, and several telehealth providers list monthly cash prices beside it. HealthRX keeps a Zepbound pricing page, Ro and Henry Meds publish their own, and noting the maintenance-dose number from two or three of them gives a real fallback rather than a guess.
Approvals expire and renewals are judged again
An approval is granted for a set period, often six or twelve months, after which the pharmacy claim rejects exactly as it did before. Renewal requests typically ask for evidence of response, so recent documented weights matter. Where criteria tightened in the interim, the renewal is measured against the new version rather than the one that produced the original approval.
Continued treatment is what sustains the effect. Maintenance trials in this class show that stopping is followed by regain, so an administrative gap has a clinical cost rather than merely an inconvenient one. Marking the expiry date at the moment of approval, and filing several weeks early, is what prevents it.
When authorization is the wrong tool
If the benefit excludes anti-obesity medication as a category, no submission succeeds, because there is no covered benefit to authorize. Recognizing that early frees the decision to be about price instead. Manufacturer self-pay channels publish cash figures for the branded product, and supervised telehealth practices including Ro, Hims and Hers and LifeMD publish flat monthly prices for compounded tirzepatide. Before treating any such figure as comparable to a copay, it is worth reading the terms posted by the provider behind it, particularly whether a licensed clinician reviews the case and whether the price holds as the dose rises. Compounded products are prepared by pharmacies rather than approved by the FDA, which does not review them for safety, effectiveness or manufacturing quality.
Frequently asked questions
Can a member file the request themselves?
Rarely. The process is built around clinical records held by the prescribing office, and most plans accept submissions only from a provider. The useful member role is obtaining the criteria, confirming the request was transmitted and to which entity, and supplying anything the chart is missing, such as records from a previous practice.
Does an approval transfer to a new plan?
Generally no. A new administrator applies its own criteria and normally requires a fresh request. Starting several weeks before the switch date, with current documentation assembled, prevents a gap between the final fill under the old plan and the first under the new one.
What is a quantity limit exception?
It is a separate request asking the plan to permit more than the standard allowance, usually because the prescribed regimen does not fit the default. It is filed like an authorization and decided on its own merits, so an approved authorization does not automatically resolve a quantity rejection at the pharmacy.
Does a sleep apnea diagnosis guarantee approval?
No. It changes which criteria apply and can open a path where a weight-only request would fail, but the plan still applies its own rules on severity, documentation and prior treatment. The sleep study report normally has to be attached rather than referenced.
How long should a decision take before following up?
Follow up once transmission is confirmed and again a few business days later. Most electronic submissions resolve inside the federal outer limits by a wide margin, so silence past a week usually indicates a missing item rather than a slow queue.
